Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;80(3):350-371.
doi: 10.1016/j.jinf.2019.11.015. Epub 2019 Nov 26.

Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease

Page E Crew  1 , Lucy McNamara  2 , Peter E Waldron  3 , Lynda McCulley  3 , S Christopher Jones  3 , Susan J Bersoff-Matcha  4
Affiliations

Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease

Page E Crew et al. J Infect. 2020 Mar.
No abstract available

Keywords: Antibiotic prophylaxis; Eculizumab; Neisseria meningitidis.

PubMed Disclaimer

Conflict of interest statement

Transparency Declaration: The authors have no potential conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Age (years) of patients at time of starting eculizumab therapy versus TTO of first meningococcal disease episode The relationship between age when patients started treatment and TTO of first meningococcal disease episode, for prophylaxis recipients and non-prophylaxis recipients. Key: Orange square = patients taking antibiotic prophylaxis with reported TTO (n=11) Blue circle = patients not taking antibiotic prophylaxis with reported TTO (n=26) Orange … dotted line = median TTO (835 days) for patients taking antibiotic prophylaxis with reported TTO (n=11) Blue --- dashed line = median TTO (333 days) for patients not taking antibiotic prophylaxis with reported TTO (n=26) Note, one patient in the “prophylaxis group” was 18 years of age with a TTO=53 days, and one patient in the “no prophylaxis group” was also 18 years of age with a TTO=53. These data points overlap on the figure.
See this image and copyright information in PMC

References

    1. Crew PE, McNamara L, Waldron PE, McCulley L, Jones SC, Bersoff-Matcha SJ. Unusual Neisseria species as a cause of infection in patients taking eculizumab. J Infect 2019; 78 (2): 113–18. - PMC - PubMed
    1. Soliris (eculizumab) [package insert]. Boston, MA: Alexion Pharmaceuticals, Inc; 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125166s431lbl.pdf. Updated June 27, 2019 Accessed on September 6, 2019.
    1. Crew PE, Abara WE, McCulley L, et al. Disseminated gonococcal infections in patients receiving eculizumab: a case series. Clin Infect Dis 2018. - PMC - PubMed
    1. McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. MMWR Morb Mortal Wkly Rep 2017; 66 (27): 734–37. - PMC - PubMed
    1. Parikh SR, Lucidarme J, Bingham C, et al. Meningococcal B Vaccine Failure With a Penicillin-Resistant Strain in a Young Adult on Long-Term Eculizumab. Pediatrics 2017; 140 (3). - PubMed

MeSH terms